ddrg/super_eurlex huggingface dataset:
Non-opposition to a notified concentration

(Case M.8982 — Ivanhoe Cambridge/PSPIB/JV)

(Text with EEA relevance)

(2021/C 81/01)

On 30 August 2018, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8982. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10194 — CDP Venture Capital/Generali Welion/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 75/06)

1. On 19 February 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Cassa Depositi e Prestiti S.p.A. (‘CDP’, Italy); — CDP Venture Capital SGR S.p.A. (‘CDP Venture Capital’, Italy), controlled by CDP; — Assicurazioni Generali S.p.A. (‘Assicurazioni Generali’, Italy); — Generali Welion S.C.A.R.L (‘Generali Welion’, Italy), controlled by Assicurazioni Generali; and — JVCo, a newly established joint venture company (‘JVCo’, Italy), jointly controlled by CDP Venture Capital and by Generali Welion. CDP Venture Capital and Generali Welion acquire, within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation, joint control of JVCo. The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are: — for CDP: financing of public bodies and initiatives promoted by them, in the acquisition of shareholdings in companies of significant national interest, in the financing of works, plants, networks and endowments for the provision of public services; — for CDP Venture Capital: direct and indirect investments, managing funds, support startups in all phases of their life cycle; — for Assicurazioni Generali: all types of insurance, nationally and internationally; — for Generali Welion: consultancy and management services for individual health and corporate welfare; and — for JVCo: the provision of residential and recreational services for the elderly, as well as wellness and assistance services.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10194 — CDP Venture Capital/Generali Welion/JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.9455 — Compass/Fazer Food Services)

(Text with EEA relevance)

(2021/C 90/01)

On 28 January 2020, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32020M9455. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.10178 — Eni/Aldro EyS/Instalaciones MD)

(Text with EEA relevance)

(2021/C 83/01)

On 5 March 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10178. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.10143 — Inter-Risco/Unavets/OneVet)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 103/12)

1. On 17 March 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Inter-Risco Sociedade de Capital de Risco, S.A. (‘Inter-Risco’, Portugal), ultimately controlled by CaixaBank (Spain) — Unavets Healthcare, S.L. (‘Unavets’, Spain), ultimately controlled by Oaktree Group (USA), — OneVet Group, SGPS, S.A (‘OneVet’, Portugal), currently controlled by Inter-Risco. Inter-Risco and Unavets acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the whole of OneVet. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Inter-Risco: private equity fund established in Portugal with interests in the hospitality, engineering and construction sector, as well as in the supply of medical-veterinary services (through OneVet) and the roasting and commercialisation of coffee. — for Unavets: veterinary services group established in Spain active in the supply of medical-veterinary services and ancillary activities in Spain. — for OneVet: veterinary services group established in Portugal active in the supply of medical-veterinary services and ancillary activities in Portugal.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10143 — Inter-Risco/Unavets/OneVet Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10151 — Linde/Sipchem/JV)

(Text with EEA relevance)

(2021/C 96/01)

On 15 March 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10151. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.10193 — OTPP/IFM/Enwave Energy Canada)

(Text with EEA relevance)

(2021/C 129/03)

On 7 April 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10193. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.9744 — Mastercard/Nets)

(Text with EEA relevance)

(2021/C 118/02)

On 17 August 2020, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation (EC) No. 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32020M9744. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10215 — CVC/Carlyle/MedRisk)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 139/05)

1. On 13 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — CVC Capital Partners SICAV-FIS S.A. (‘CVC’, Luxembourg), — The Carlyle Group, Inc. (‘Carlyle’, United States), — MedRisk Holdco, LLC (‘MedRisk’, United States), controlled by Carlyle. CVC and Carlyle acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of MedRisk. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for CVC: management of investment funds and platforms holding interests in companies active in various industries primarily in Europe, United States, and the Asia-Pacific region, — for Carlyle: global alternative asset manager of funds active globally across different investment disciplines, including corporate private equity, real estate, and natural resources funds, — for MedRisk: supplier of managed physical therapy for the workers’ compensation industry and related market sectors in the United States.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for the treatment of certain concentrations under Council Regulation (EC) No 139/2004, (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10215 — CVC/Carlyle/MedRisk Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10159 — Infosys/Daimler (Certain Assets and Personnel))

(Text with EEA relevance)

(2021/C 132/01)

On 8 April 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10159. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10257 — Clearlake/TA Associates/Infogix)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 154/11)

1. On 22 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Clearlake Capital Group, L.P. (‘Clearlake’, USA), — TA Associates Management, L.P. (‘TA Associates’, USA), — Infogix, Inc. (‘Infogix’, USA), controlled by Thoma Bravo L.P. (‘Thoma Bravo’, USA). Clearlake and TA Associates acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Infogix. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Clearlake: private equity investment firm, with portfolio companies active in software and technology-enabled services, energy and industrials, and consumer products/services, — for TA Associates: private equity investment firm, with portfolio companies active in selected industries, including business services, consumer, financial services, healthcare and technologies, and — for Infogix: provider of data management solutions, including data governance, data quality and data analytics tools.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10257 – Clearlake/TA Associates/Infogix Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10060 — Francisco Partners/Marlin Equity Partners/Conan Holdco)

(Text with EEA relevance)

(2021/C 147/01)

On 11 February 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10060. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.10182 — SADC/Cognite/JV)

(Text with EEA relevance)

(2021/C 187/03)

On 7 May 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10182. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10253 — Colony Capital/Goldman Sachs/Japan JV)

(Text with EEA relevance)

(2021/C 170/08)

1. On 29 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Colony Capital, Inc. (‘Colony Capital’, USA), — The Goldman Sachs Group, Inc. (‘Goldman Sachs’, USA), — Japan JV (Singapore). Colony Capital and Goldman Sachs acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the newly created joint venture Japan JV. The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are: — for Colony Capital: management of a global portfolio composed of, amongst other, investments in digital infrastructure, including macro cell towers, data centres, small cell networks and fibre networks, — for Goldman Sachs: global investment banking, securities and investment management. It provides a range of banking, securities and investment services worldwide to a substantial and diversified client base. — for Japan JV: construction, ownership and operation of green field data centres, or the acquisition of data centre assets, in Japan.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10253 — Colony Capital/Goldman Sachs/Japan JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10208 — The Coca-Cola Company/Coca-Cola HBC/WABI CCH JV)

(Text with EEA relevance)

(2021/C 197/03)

On 19 May 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10208. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.